Certain antipsychotics linked with increased risk of gestational diabetes
Study suggests that use of olanzapine or quetiapine during pregnancy is linked with development of gestational diabetes.
Women who continue taking olanzapine or quetiapine during pregnancy are more likely to develop gestational diabetes than those who discontinue atypical antipsychotic medication, according to a study in the American Journal of Psychiatry (7 May 2018).
The research included data on 1.5 million pregnancies of non-diabetic mothers who had received a prescription for an antipsychotic drug in the 3 months before pregnancy.
The findings showed that women who continued taking olanzapine in the first 20 weeks of pregnancy had a 61% increased risk of gestational diabetes and those who continued taking quetiapine had a 28% increased risk, compared with women who discontinued these drugs.
However, there was no association between continued use of aripiprazole, ziprasidone or risperidone and gestational diabetes.
“Further studies are needed in order to understand the potential effect of switching antipsychotic agents during pregnancy on the risk for gestational diabetes,” said the authors.
“Such information would aid treatment decisions pertaining to women for whom treatment discontinuation is not an option.”
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205057
Recommended from Pharmaceutical Press